Rational Pharmacotherapy in Cardiology

Advanced search

Postural Orthostatic Tachycardia Syndrome as a Manifestation of Post-COVID-19 Syndrome

Full Text:


The pandemic of coronavirus infection, the complex and insufficiently studied mechanisms of which cause disorders in the functions of many organs and systems of the body, has led to the emergence of new problems that are far from being resolved. Researchers note the difficulty in predicting the course of the disease and outcome due to the detection of many symptoms that arose at the height of the disease and persisted for 3-6 months after recovery. The term "post-COVID-19syndrome" has appeared, reflecting the condition of a patient who has undergone COVID-19, with a negative PCR test, and with symptoms lasting more than 12 weeks from the onset of the disease, which cannot be explained by an alternative diagnosis. Postural orthostatic tachycardia as a manifestation of the post-COVID-19syndrome has been described in young women who have undergone coronavirus infection of varying severity. In the case of the development of the syndrome of postural orthostatic tachycardia, the quality of life deteriorates, and the ability to work of patients is limited. There is no evidence base for drug therapy of postural tachycardia syndrome, in most cases empirical drug and non-drug methods of treatment are used.

About the Author

E. L. Trisvetova
Belarusian State Medical University

Eugenia L. Trisvetova



1. Johansson M, Stahberg M, Runold M, et al. Long-Haul Post-COVID-19 Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia Syndrome: The Swedish Experience. Am Coll Cardiol Case Rep. 2021;3(4):573-80. DOI:10.1016/j.jaccas.2021.01.009.

2. Miglis MG, Prieto T, Shaik R, et al. A case report of postural tachycardia syndrome after COVID-19. Clin Auton Res. 2020;30(5):449-51. DOI:10.1007/s10286-020-00727-9.

3. Schmidt LL, Karabin BL, Malone AC. Postural Orthostatic Tachycardia Syndrome (POTS): Assess, Diagnose, and Evaluate for POTS Treatment (ADEPT). Integr Med Int. 2017;4(3-4):142-53. DOI:10.1159/000484205.

4. Schondorf R, Low PA. Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia? Neurology. 1993;43(1):132-7. DOI:10.1212/wnl.43.1_part_1.132.

5. Freeman R, Weiling W, Axelrod F, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69-72. DOI:10.1007/s10286-011-0119-5.

6. Garland EM, Celedonio JE, Raj SR. Postural tachycardia syndrome: beyond orthostatic intolerance. Curr Neurol Neurosci Rep. 2015;15(9):60. DOI:10.1007/s11910-015-0583-8.

7. Low PA, Sandroni P, Joyner M, Shen VK. Postural Tachycardia Syndrome (POTS). J Cardiovasc Electrophysiol. 2009;20(3):352-8. DOI:10.1111/j.1540-8167.2008.01407.x

8. Robertson D. The epidemic of orthostatic tachycardia and orthostatic intolerance. Am J Med Sci. 1999;317(2):75-7. DOI:10.1016/s0002-9629(15)40480-X.

9. Grubb BP. Postural tachycardia syndrome. Circulation. 2008;117(21):2814-17. DOI:10.1161/CIRCULATIONAHA.107.761643.

10. Sheldon RS, Grubb BP, Olshansky B, et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015;12(6):e41-e63. DOI:10.1016/j.hrthm.2015.03.029.

11. Arnold AC, Ng J, Raj SR. Postural tachycardia syndrome - diagnosis, physiology, and prognosis. Auton Neurosci. 2018;215:3-11. DOI:10.1016/j.autneu.2018.02.005.

12. Thieben MJ, Sandroni P, Sletten DM, et al. Postural orthostatic tachycardia syndrome: The Mayo clinic experienceс. Mayo Clin Proc. 2007;82(3):308-13. DOI:10.4065/82.3.308.

13. Peltier AC, Garland A, Raj SR. Distal sudomotor findings in postural tachycardia syndrome. Clin Auton Res. 2010;20(2):93-9. DOI:10.1007/s10286-009-0045-y.

14. Devigili G, Tugnoli V, Penza P, et al. The diagnostic criteria for small fiber neuropathy: from symptoms to neuropathology. Brain. 2008;131(Pt7):1912-25. DOI:10.1093/brain/awn093.

15. Shibao C, Arzubiaga C, Roberts LJ, et al. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension. 2005;45(3):385-90. DOI:10.1161/01.HYP.0000158259.68614/40.

16. Okamoto LE, Raj SR, Gamboa A, et al. Sympathetic activation is associated with increased Il-6, but not crp in the absence of obesity: Lessons from postural tachycardia syndrome and obesity. Am J Physiol Heart Circ Physiol. 2015;309(12):H2098-2107. DOI:10.1152/ajpheart.00409.2015.

17. Shannon JR, Flatten NL, Jordan J, et al. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med. 2000;342(8):541-9. DOI:10.1056/NEJM200002243420803.

18. Doherty T, White AA. Postural orthostatic tachycardia syndrome and the potential role of mast cell activation. Auton Neurosci. 2018;215:83-8. DOI:10.1016/jautneu.2018.05.001.

19. Stewart JM, Glover JL, Medow MS. Increased plasma angiotensin II in postural tachycardia syndrome (POTS) is related to reduced blood flow and blood volume. Clin Sci (Lond). 2006;110(2):255-63. DOI:10.1042/CS20050254.

20. Raj SR, Biaggioni I, Yamhure PC, et al. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Ciculation. 2005;111(13):1574-82. DOI:10.1161/0.CIR.0000160356973.5D.

21. Mustafa HI, Raj SR, Diedrich A, et al. Altered systemic hemodynamic and baroreflex response to angiotensin II in postural tachycardia syndrome. Circ Arrhythm Electrophysiol. 2012;5(1):173-80. DOI:10.1161/CIRCEP.111.965343.

22. Tank J, Baevsky RM, Funtova II, et al. Orthostatic heart rate responses after prolonged space flights. Clin Auton Res. 2011;21(2):121-24. DOI:10.1007/s10286-010-0106-2.

23. Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet Part C Semin Med Genet. 2017;175(1):8-26. DOI:10.1002/ajmg.c.31552.

24. Castori M, Sperduti I, Celletti C, et al. Symptom and joint mobility progression in the joint hypermobility syndrome (Ehlers-Danlos syndrome, hypermobility type). Clin Exp Rheumatol. 2011;29(6):998-1005.

25. Hakim A, O‘Callagham C, De Wandele I, et al. Cardiovascular Autonomic Dysfunction in Ehlers-Danlos Syndrome-Hypermobile Type. Am J Med Genet Part C Semin Med Genet. 2017;175(1):168-74. DOI:10.1002/ajmg.c.31543.

26. Bryarly M, Phillips LT, Fu Q, et al. Postural orthostatic tachycardia syndrome: JACC focus seminar. J Am Coll Cardiol. 2019;73(10):1207-28. DOI:10.1016/j.jacc.2018.11.059.

27. Gunning WT, Stepkowski SM, Kramer PM, et al. Inflammatory Biomarkers in Postural Orthostatic Tachycardia Syndrome with Elevated G-Protein-Coupled Receptor Autoantibodies. J Clin Med. 2021;10(4):623. DOI:10.3390/jcm10040623.

28. Fedorovsky A. Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management. J Intern Med. 2019;285(4):352-66. DOI:10.1111/joim.12852.

29. Blitshteyn S, Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. Immunol Res. 2021;69(2):205-11. DOI:10.1007/s12026-021-09185-5.

30. Kanjwal K, Jamal S, Kichloo A, Grubb BP. New-onset postural orthostatic tachycardia syndrome following coronavirus disease 2019 infection. J Innov Card Rhythm Manag. 2020;11(11):4302-4. DOI:10.19102/icrm.202.111102.

31. Novak P. Post COVID-19 syndrome associated with orthostatic cerebral hyperfusion syndrome, small fiber neuropathy and benefit of immunotherapy: a case report. Neurological Sci. 2020;21:100276. DOI:10.1016/j.ensci.2020.100276.

32. Miller AJ, Raj SR. Pharmacotherapy for postural tachycardia syndrome. Auton Neurosci. 2018;215:28-36. DOI:10.1016/j.autneu.2018.04.008.

33. Taub R, Zadourian A, Lo HC, et al. Randomized Trial of Ivabradine in Patients with Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. J Am Coll Cardiol. 2021;77(7):861-71. DOI:10.1016/j.jacc.2020.12.029.

34. Molderings GJ, Haenisch B, Brettner S, et al. Pharmacological treatment options for mast cell activation disease. Naunyn-Schmiedeberg’s Arch Pharmacol. 2016;389(7):671-94. DOI:10.1007/s00210-016-1247-1.

35. Sokol KC, Ghazi A, Kelly BC, Grant JA. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. J Allergy Clin Immunol Pract. 2014;2(3):266- 70. DOI:10.1016/j.jaip.2014.03.009.

36. Coffin ST, Black BK, Biaggioni I, et al. Desmopressin acutely decreases tachycardia and improves symptoms in the postural tachycardia syndrome. Heart Rhythm. 2012;9(9):1484-90. DOI:10.1016/j.hrthm.2012.05.002.

37. Kanjwa l K, Saeed B, Karabin B, et al. Erythropoietin in the treatment of postural orthostatic tachycardia syndrome. Am J Ther. 2012;19(2):92-5. DOI:10.1097/MJT. 0b013e3181ef621a.

38. Zhao J, Tang C, Jin H, Du J. Plasma copeptin and therapeutic effectiveness of midodrine hydrochloride on postural tachycardia syndrome in children. J Pediatr. 2014;165(2):290-94.e1. DOI:10.1016/j.jpeds.2014.04.032.

39. Raj SR, Black BK, Biaggioni I, et al. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation. 2009;120(9):725-34. DOI:10.1161/CIRCULATIONAHA.108.846501.

40. Raj SR. Postural tachycardia syndrome (POTS). Circulation. 2013;127(23):2336-427 DOI:10.1161/CIRCULATIONAHA.112.144501.

41. Ruzieh M, Sirianni N, Ammari Z, et al. Ivabradine in the treatment of postural tachycardia syndrome (POTS), a single center experience. Pacing Clin. Electrophysiol. 2017;40(11):1242-45. DOI:10.1111/pace.13182.

42. Tahir F, Arif TB, Majid Z, et al. Ivabradine in Postural Orthostatic Tachycardia Syndrome: A Review of the Literature. Cureus. 2020;12(4):e7868. DOI:10.7759/cureus.7868.


For citations:

Trisvetova E.L. Postural Orthostatic Tachycardia Syndrome as a Manifestation of Post-COVID-19 Syndrome. Rational Pharmacotherapy in Cardiology. 2022;18(2):200-208. (In Russ.)

Views: 550

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)